33,493 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Bought by Wellington Management Group LLP

Wellington Management Group LLP acquired a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 33,493 shares of the company's stock, valued at approximately $583,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. R Squared Ltd purchased a new position in shares of Travere Therapeutics during the 4th quarter worth $53,000. Victory Capital Management Inc. purchased a new position in Travere Therapeutics during the fourth quarter worth about $182,000. Baader Bank Aktiengesellschaft acquired a new stake in shares of Travere Therapeutics during the fourth quarter valued at about $192,000. Entropy Technologies LP purchased a new stake in shares of Travere Therapeutics in the 4th quarter valued at approximately $214,000. Finally, E Fund Management Co. Ltd. acquired a new position in shares of Travere Therapeutics in the 4th quarter worth approximately $217,000.

Insider Transactions at Travere Therapeutics

In other news, CFO Christopher R. Cline sold 5,192 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $20.12, for a total value of $104,463.04. Following the completion of the transaction, the chief financial officer now owns 90,038 shares in the company, valued at approximately $1,811,564.56. This represents a 5.45 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP William E. Rote sold 2,437 shares of the stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total transaction of $47,424.02. Following the completion of the transaction, the senior vice president now directly owns 83,170 shares in the company, valued at $1,618,488.20. This trade represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 188,877 shares of company stock valued at $4,147,627. 3.75% of the stock is currently owned by corporate insiders.

Travere Therapeutics Stock Up 2.4 %

Shares of TVTX stock traded up $0.35 during trading hours on Friday, reaching $14.92. 1,101,182 shares of the stock were exchanged, compared to its average volume of 1,522,870. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $25.29. The business's fifty day moving average is $18.89 and its two-hundred day moving average is $18.59. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The firm has a market capitalization of $1.32 billion, a P/E ratio of -3.64 and a beta of 0.84.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.15). The firm had revenue of $74.79 million for the quarter, compared to analysts' expectations of $72.38 million. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. As a group, research analysts expect that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Evercore ISI lifted their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Canaccord Genuity Group lifted their price objective on Travere Therapeutics from $45.00 to $47.00 and gave the company a "buy" rating in a research note on Thursday, April 10th. JPMorgan Chase & Co. increased their target price on Travere Therapeutics from $42.00 to $44.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Bank of America raised their target price on Travere Therapeutics from $29.00 to $31.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Travere Therapeutics in a research note on Thursday, April 3rd. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, Travere Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $32.08.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.